Lupin Of India Counts On Global Generics Push To Increase Profits
This article was originally published in PharmAsia News
The expansion by India's Lupin into U.S. and Japan markets is generating a company forecast of an increase of as much as 37 percent in profit and sales during the current financial year. Lupin is relying on the push in the world's two largest markets to get patients to use generics to drive its profit increase. The global market for generics is growing at double that of branded drugs because of perceived government needs to trim expenses. Lupin Managing Director Kamal Sharma said his company also plans to acquire more firms and technology to help meet the global demand. (Click here for more
You may also be interested in...
Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.